CurveBeam AI Limited (ASX: CVB) is an Australian medical-imaging technology company developing the HiRise™ platform. It is raising up to A$1.4 million through an SPP shortfall placement at A$0.018 per share to fund Chinese market-launch preparation, product enhancements, supply-chain activities, sales and marketing, and working capital.

SPP Shortfall Placement to raise gross proceeds of up to ~A$1,400,000, reflecting the issue of up to ~77 million fully paid ordinary shares (‘SPP Shares’) at A$0.018 per share

Discount

18.2% discount to the last traded share price of A$0.022 on 15 September 2026 and a discount of 36.5% to the 15-day VWAP of A$0.028.

SPP Shares offered at A$0.018 represents a 10.0% discount to the offer price under the A$5.0m placement announced to the ASX on 8th July 2026

Indicative Use of Funds (Funds raised by the SPP, together with the A$5m proceeds of the Placement):

• Sales & marketing expenses including China market launch preparation for the HiRiseTM;

• Research & development costs including product enhancements for the HiRiseTM;

• Supply chain costs including preparing for China market launch; and

• General working capital purposes including capital raising fees.

CurveBeam AI Limited (ASX: CVB) is an Australian-listed medical imaging technology company focused on advancing its HiRise™ platform. The company is pursuing commercial expansion and product development initiatives, with a particular emphasis on preparing for a prospective China market launch. Its current funding program comprises an SPP shortfall placement of up to approximately A$1.4 million at A$0.018 per share, alongside a previously announced A$5.0 million placement. Proceeds are earmarked for sales and marketing, China launch preparation, supply-chain readiness, HiRise™ product enhancements, and general working capital, including transaction costs. The company had 768.1 million ordinary shares on issue before the shortfall placement and a pre-offer market capitalisation of approximately A$16.9 million. The placement is available only to sophisticated and professional investors.

• Growth funding for commercialisation: CurveBeam AI is raising up to approximately A$1.4 million via an SPP shortfall placement, complementing the A$5.0 million placement announced in July 2026, to support the next stage of commercial and operational execution.

• China launch preparation: A stated focus of the capital program is preparation for the HiRise™ platform’s China market launch, including sales and marketing activity and supply-chain readiness. This provides a defined pathway to pursue a potentially significant new geography.

• Continued HiRise™ investment: Funds are earmarked for research and development, including HiRise™ product enhancements, supporting ongoing product evolution alongside commercial expansion.

• Discounted entry point: The A$0.018 issue price is a 18.2% discount to the A$0.022 last traded price on 15 September 2026 and a 36.5% discount to the 15-day VWAP of A$0.028.

• Existing capital base and liquidity: Prior to the offer, CurveBeam AI had 768.1 million shares on issue and an implied market capitalisation of approximately A$16.9 million, offering exposure to the company at a relatively early commercialisation-stage valuation.

• Near-term catalysts: Potential catalysts include completion of the shortfall placement, allocation of capital toward China market-entry preparation, HiRise™ product upgrades, and progress in sales, marketing and supply-chain execution.

• Sophisticated-investor placement: The offer is being made to sophisticated and professional investors and is not underwritten; investors should regard it as speculative, conduct independent due diligence, and consider dilution and execution risks.